Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 63.99

+4.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doc Bones who wrote (6430)	5/26/2002 1:14:15 AM
From: Ian@SI	Read Replies (1) of 52153

Cash-Rich Biotechs (Just parking this table on this thread) This yearÕs selloff in the biotechnology sector has left many stocks trading at or near their net cash value. Some investors like the prospects for Celera Genomics, CV Therapeutics and Medarex. Watch cash-burn rates, however, because all these companies are now losing money. 52 Week Mkt. Value Net Cash Net Cash Book Value/ Earnings Company Price as of 5/23 Hi - Lo ($ bil) ($ bil) Share Share 2002E* Comments Abgenix 14.30 47 - 11 1.24 0.44 $ 5.00 $ 8.70 -$1.59 Hurt by psoriasis drug failure Arena Pharm 7.75 36 - 7 0.21 0.22 8.00 9.74 -0.97 Cash-rich gene tech. firm Avigen 9.68 24 - 7 0.19 0.14 7.00 7.50 -1.60 Focused on hemophilia cure Celera Genomics 14.89 50 - 12 1.02 0.91 13.35 16.15 -1.51 Gene mapper now drug creator Curagen 8.21 42 - 7 0.39 0.33 6.70 6.90 -1.87 Another cash-rich gene firm CV Therapeutics 24.93 61 - 21 0.64 0.26 10.00 11.50 -4.22 Angina drug could be lucrative Human Genome 17.96 77 - 13 2.30 1.10 8.50 9.70 -1.41 Using genomics to find drugs ImClone Systems 10.50 76 - 9 0.77 0.18 2.40 -0.40 -1.29 CEO of Erbitux maker just quit Intermune 28.50 53 - 21 0.90 0.26 8.50 8.90 -3.60 Fibrosis drug has big potential Maxygen 10.47 23 - 9 0.36 0.23 6.90 7.45 -1.08 Multiple sclerosis drug in works Medarex 10.41 33 - 7 0.77 0.28 3.74 6.25 -0.59 Asset-rich antibody producer Millenium Pharm 17.95 45 - 15 5.02 1.30 5.20 11.80 -0.73 Merged with Cor Therapeutics Oxford Glycosciences 5.80 17 - 4 0.32 0.26 4.70 5.11 -0.70 Working on Gaucher disease Praecis Pharm 3.11 32 - 2 0.16 0.26 5.00 5.30 -1.53 Cash exceeds market value Protein Design Lab 13.05 46 - 10 1.15 0.49 5.30 6.05 -0.20 Focused on antibody therapy Transkaryotic Ther 41.09 47 - 22 1.41 0.37 11.00 12.25 -2.10 Promising Fabry disease drug

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next